PROJECT NUMBER
•
2022-135
PROJECT STATUS:
CURRENT
ORGANISATION:
University of Adelaide
TAGS
SPECIES
3 results
Minor use permit for praziquantel for non-Seriola finfish
Project number:
2021-029
Project Status:
Current
Budget expenditure:
$75,000.00
Principal Investigator:
Marty R. Deveney
Organisation:
University of Adelaide
Ectoparasite infections are major production limiting issues in aquaculture. The only products permitted for use in Australia against ectoparasites of finfish are formalin, sodium percarbonate and hydrogen peroxide. These products can have negative effects on fish gills and skin and result in direct mortality when elevated chemical dose or duration of exposure are sub-optimal or improperly calculated. Against some flatworm parasites formalin, sodium percarbonate and hydrogen peroxide have low efficacy. Praziquantel (PZQ) immersion treatments have been found to be both safe and efficacious for current fish flatworms applications, at a low dosage and duration of exposure, with a lesser or equivalent environmental impact. The aquaculture industry and the Subcommittee for Aquatic Animal Health identified access to PZQ for finfinfish as a priority. Treatment forms a vital part of parasite management in aquaculture along with husbandry practices designed to interrupt parasite lifecycles. Appropriate use of PZQ can help alleviate reduced growth and food conversion and improves welfare associated with flatworm parasite infestation. A permit obtained as part of this project will facilitate better parasite management, improve production and fish welfare. APVMA provided pre-application advice on PZQ. Available data for PZQ can satisfy the APVMA module requirements for efficacy, chemistry and manufacture, toxicology, trade and occupational health and safety. These are available in published literature, a range of industry studies of animals treated off-label and laboratory studies. There is a lack of data to satisfy the requirements mainly in the environment modules and the target animal safety module.
PZQ is registered as an active ingredient, and for use in cats, dogs, horses, cattle, pigs and sheep in Australia. An unregistered product is manufactured by VetLab Autopak into two permitted products for use in kingfish as an in-feed (PER#87336) or immersion (PER#87833) treatments. The APVMA PAA assessed PZQ as suitable for assessment for use in finfish.
Minor use permit for erythromycin in finfish
Project number:
2021-027
Project Status:
Current
Budget expenditure:
$95,000.00
Principal Investigator:
Marty R. Deveney
Organisation:
University of Adelaide
There are no antimicrobials permitted or registered for use in finfish in Australia effective against gram positive bacteria (e.g. Streptococcus and Lactococcus). In finfish aquaculture, erythromycin (ERYC) is the best antimicrobial against gram positive organisms. The aquaculture industry and the Subcommittee for Aquatic Animal Health identified access to this product for finfinfish as a priority. Bacterial diseases are increasingly managed by eradication, maintenance of animals of specified health status, vaccination, and good hygiene, but antimicrobial therapy remains vital for treating bacterial diseases in finfish aquaculture. Appropriate use of antimicrobials can alleviate illness and suffering, improve welfare, increase speed of recovery, reduce spread of infection. Use of ERYC is not intended for prophylactic treatment, but as a tool for veterinarians to manage disease outbreaks. Use in South Australia, for example, is sporadic (~1 to 2 times per 3-5 years for a sector). The Aquaculture industry is committed to Australia's antimicrobial strategy, and as required by APVMA this proposal includes an antimicrobial resistance risk assessment. Available data for ERYC can satisfy the APVMA module requirements for efficacy, chemistry and manufacture, toxicology, trade and occupational health and safety. These are available in published literature, a range of industry studies of animals treated off-label and laboratory studies. There is a lack of data to satisfy the requirements mainly in the environment modules and the antimicrobial resistance risk assessment.
ERYC was ranked low by the Expert Advisory Group on Antimicrobial Assessment (EAGAR) as an antimicrobial for which there are a reasonable number of alternative agents in different classes available to treat most infections. Although it is listed on the WHO list of essential medicines, it is registered for use in cattle, pigs and sheep (APVMA #84160) and poultry (APVMA #50742) in Australia and the WHO list can be modified locally to suit the availability and sophistication of the animal and human health systems in WHO member countries. The APVMA PAA assessed ERYC as suitable for assessment for use in finfish.
View Filter
